Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K H Moore

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Journal of Clinical Pharmacology|April 18, 2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjectsB M Sadler, G E Chittick, R E Polk, et al.
AIDS (London, England)|April 26, 2000
Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study GroupC Bhadrakom, R J Simonds, J V Mei, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
The Journal of Infectious Diseases|October 21, 1998
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspringJ Moodley, D Moodley, K Pillay, et al.
Anesthesiology|January 1, 1997
Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model developmentC F Minto, T W Schnider, T D Egan, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Cancer Investigation|January 1, 1991
Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinomaJ A Sosman, J A Hank, K H Moore, et al.
Cancer|December 15, 1990
The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2M R Albertini, J A Sosman, J A Hank, et al.
Journal of Clinical Pharmacology|April 18, 2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjectsB M Sadler, G E Chittick, R E Polk, et al.
AIDS (London, England)|April 26, 2000
Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study GroupC Bhadrakom, R J Simonds, J V Mei, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1993
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancerC Gambacorti-Passerini, J A Hank, M R Albertini, et al.
The Journal of Infectious Diseases|October 21, 1998
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspringJ Moodley, D Moodley, K Pillay, et al.
Anesthesiology|January 1, 1997
Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model developmentC F Minto, T W Schnider, T D Egan, et al.
Pageof 11